Báo cáo thường niên năm 2023 của Puma Biotechnology Inc

Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors … More ; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients.